By JUPITER – a potential new patient population opens up for Crestor
This article was originally published in Scrip
Executive Summary
AstraZeneca's hypolipaemic Crestor (rosuvastatin) could have a new role in patients with normal LDL-cholesterol levels but elevated CRP levels, after the full data from the JUPITER study showed that therapy with the drug reduced by 44% the combined risk of heart attack, stroke, unstable angina/revascularisation and cardiovascular death in this population.